Abivax SA (ABVX) | Financial Analysis & Statements
Abivax SA | Mid-cap | Healthcare
Abivax SA | Mid-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-173.0M
Net Income
-176.2M
EPS (Diluted)
-€2.80
Balance Sheet Metrics
Total Assets
205.2M
Total Liabilities
164.6M
Shareholders Equity
40.6M
Debt to Equity
4.06
Cash Flow Metrics
Operating Cash Flow
-154.1M
Free Cash Flow
-154.7M
Revenue & Profitability Trend
Abivax SA Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | 50.8M | 45.5M | 33.8M |
| Gross Profit | - | - | -50.8M | -45.5M | -33.8M |
| Operating Expenses | 173.0M | 127.4M | 51.2M | 41.4M | 4.1M |
| Operating Income | -173.0M | -127.4M | -51.2M | -41.4M | -38.0M |
| Pre-tax Income | -176.2M | -147.7M | -60.7M | -42.5M | -40.1M |
| Income Tax | 0 | 0 | 0 | 0 | -2.6M |
| Net Income | -176.2M | -147.7M | -60.7M | -42.5M | -37.6M |
| EPS (Diluted) | -€2.80 | -€3.43 | -€3.18 | -€2.75 | -€2.62 |
Income Statement Trend
Abivax SA Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 170.7M | 286.0M | 36.2M | 75.5M | 37.7M |
| Non-Current Assets | 34.6M | 41.1M | 39.4M | 33.7M | 33.6M |
| Total Assets | 205.2M | 327.1M | 75.5M | 109.2M | 71.3M |
| Liabilities | |||||
| Current Liabilities | 92.8M | 88.1M | 51.5M | 32.3M | 19.4M |
| Non-Current Liabilities | 71.8M | 42.9M | 16.9M | 51.0M | 34.0M |
| Total Liabilities | 164.6M | 131.1M | 68.4M | 83.3M | 53.4M |
| Equity | |||||
| Total Shareholders Equity | 40.6M | 196.0M | 7.2M | 25.9M | 17.9M |
Balance Sheet Composition
Abivax SA Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -176.2M | -147.7M | -60.7M | -42.5M | -38.0M |
| Operating Cash Flow | -154.1M | -96.1M | -56.9M | -41.6M | -28.4M |
| Investing Activities | |||||
| Capital Expenditures | -640.0K | -265.0K | -288.0K | -47.0K | -282.0K |
| Investing Cash Flow | 7.6M | -19.1M | -12.3M | -6.2M | -575.0K |
| Financing Activities | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | - |
| Financing Cash Flow | 35.9M | 340.6M | 36.2M | 84.6M | 49.9M |
| Free Cash Flow | -154.7M | -97.4M | -54.3M | -45.1M | -30.7M |
Cash Flow Trend
Abivax SA Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.96
Forward P/E
-3.52
Price to Book
-52.78
Price to Sales
31.33
PEG Ratio
-3.52
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-4,865.98%
Return on Equity
-196.12%
Return on Assets
-48.60%
Financial Health
Current Ratio
1.26
Debt to Equity
-16.16
Beta
1.51
Per Share Data
EPS (TTM)
-€2.95
Book Value per Share
-€0.10
Revenue per Share
€0.17
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| abvx | 331.7M | -1.96 | -52.78 | -196.12% | 0.00% | -16.16 |
| Medincell S.A | 565.5M | -18.81 | - | 61.33% | -66.50% | -1.44 |
| Valneva SE | 409.5M | 70.64 | 2.11 | -44.11% | -43.21% | 120.48 |
| BNP Paribas Easy | 456.7M | 15.91 | - | -96.39% | -27.22% | 2.22 |
| Inventiva S.A | 379.0M | -0.88 | -0.99 | 172.73% | 0.00% | -1.70 |
| Viridian | 415.4M | 50.43 | 0.40 | 0.93% | 2.05% | 103.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.